Articles

  • 2 days ago | healio.com | Richard Gawel

    Key takeaways:EVEREST represents the first head-to-head study of these biologics for CRSwNP. Differences between the biologics were seen as early as 4 weeks. Greater improvements in lung function were seen with dupilumab. Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, according to an abstract presented at European Academy of Allergy & Clinical Immunology Congress 2025.

  • 2 days ago | healio.com | Richard Gawel

    Key takeaways: Patients used the device for 60 days, and effects persisted for 6 months. 71% of patients reported improved Neck Disability Index scores. Adverse events were not serious and primarily included skin irritation. MINNEAPOLIS — Patients with occipital headache experienced relief with 60 days of peripheral nerve stimulation, according to data presented at the American Headache Society 67th Annual Scientific Meeting.

  • 3 days ago | healio.com | Richard Gawel

    Key takeaways: 86.9% of patients saw a 50% or greater reduction in pain scores from day 1 to day 3. The addition of antiseizure medications to the infusion did not change these reductions. MINNEAPOLIS — Patients with trigeminal neuralgia experienced relief with IV magnesium and methocarbamol, according to data presented at the American Headache Society 67th Annual Scientific Meeting.

  • 4 days ago | healio.com | Richard Gawel

    Key takeaways: Remote electrical neuromodulation, controlled by app, is designed for acute and preventive treatment of migraine. Earlier treatment led to more freedom from photophobia and phonophobia. MINNEAPOLIS — Patients with migraine experienced more relief when they used remote electrical neuromodulation within an hour of an attack, according to a poster presented at the American Headache Society 67th Annual Scientific Meeting.

  • 4 days ago | healio.com | Richard Gawel

    Key takeaways: Barzolvolimab prevents the binding of stem cell factor to KIT to inhibit and deplete mast cells. The persistence of improvements 28 weeks after the last dose suggests a disease-modifying effect. Patients with chronic spontaneous urticaria saw complete response and improved quality of life 7 months after treatment with barzolvolimab, according to data presented at European Academy of Allergy & Clinical Immunology Congress 2025.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →